t needs, we also recognize that, ultimately, to fully maximize our effectiveness -- and our clients' return on investment -- we need to come at these patient recruitment issues with insight," continued Brescia, "The kind of insight that only comes from understanding a country's or region's culture, traditions, and attitudes about health and healthcare. It's a process we found to be invaluable after opening our offices in London and in Prague."
BBK Worldwide -- Osaka, G.K., will be strategically placed in the city that is fast becoming the center of Japan's biotechnology industry. In the fall of 2008, the local prefectural government launched an initiative to form a biomedicine joint research group, including firms and universities in the fields of biomedicine and pharmaceutical development. Several major global pharmaceutical companies are also based in the city, or have established operations there. "Osaka seemed the ideal place to establish the operational base for our building of bridges -- between recruitment barriers and enrollment solutions, and between cultures and business practices," said Jeremy Buchman, who will head up the Osaka office. "And, it is an optimal location from which to help operationalize our patient recruitment efforts on behalf of our clients throughout the Asia-Pacific region."
This past fall, JETRO (Japan External Trade Organization), an official government organization, began consulting closely with BBK, helping the company with registration, visa preparations, and meeting arrangements with industry organizations in Osaka. "We are very excited about BBK establishing a presence in Japan. We're certain that BBK's knowledge and experience in patient recruitment will have a positive effect on the Japanese clinical trials marketplace. We truly hope that BBK has continuous success," said Taku Sato, Director of Business Development, JETRO New York.
The opening of BBK Worldwide -- Osaka, G.K., Page: 1 2 3 Related biology technology :1
. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress2
. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says3
. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions4
. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions5
. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia6
. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company7
. Oregon Health & Science University Knight Cancer Institute Enhances Patient Care With Monaco(R) Radiation Treatment Planning System8
. Mayo Clinic CEO Offers New Vision for Personalized Patient Care9
. Photos: Project Runways Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldnt Let Psoriasis Impact Personal Style10
. NPSF Issues New Universal Patient Compact During Patient Safety Awareness Week11
. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients